Last reviewed · How we verify
nadroparin
At a glance
| Generic name | nadroparin |
|---|---|
| Also known as | nadroparin is a low molecular weight heparin, Low moleculor weight hepatin, Fraxiparine, Fraxiparin |
| Sponsor | Onze Lieve Vrouwe Gasthuis |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Deep venous thrombosis
Common side effects
Key clinical trials
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Reduced Anticoagulation Targets in ECLS (RATE) (PHASE3)
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events (NA)
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PHASE3)
- Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine (PHASE2)
- Kinetics of Extracellular Vesicles in Hemodialysis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |